Andrew Guggenhime is PRESIDENT AND CFO of Vaxcyte, Inc.. Currently has a direct ownership of 127,173 shares of PCVX, which is worth approximately $4.8 Million. The most recent transaction as insider was on Mar 03, 2025, when has been sold 3,809 shares (Common Stock) at a price of $72.1 per share, resulting in proceeds of $274,628. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 127K
16.15% 3M change
32.92% 12M change
Total Value Held $4.8 Million

ANDREW GUGGENHIME Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 03 2025
SELL
Payment of exercise price or tax liability
$274,628 $72.1 p/Share
3,809 Reduced 2.91%
127,173 Common Stock
Feb 28 2025
SELL
Payment of exercise price or tax liability
$92,735 $73.02 p/Share
1,270 Reduced 0.96%
130,982 Common Stock
Feb 27 2025
BUY
Grant, award, or other acquisition
-
22,761 Added 14.68%
132,252 Common Stock
Feb 18 2025
SELL
Open market or private sale
$672,880 $84.11 p/Share
8,000 Reduced 6.81%
109,491 Common Stock
Feb 18 2025
BUY
Exercise of conversion of derivative security
$42,800 $5.35 p/Share
8,000 Added 6.37%
117,491 Common Stock
Jan 21 2025
SELL
Open market or private sale
$696,080 $87.01 p/Share
8,000 Reduced 6.81%
109,491 Common Stock
Jan 21 2025
BUY
Exercise of conversion of derivative security
$42,800 $5.35 p/Share
8,000 Added 6.37%
117,491 Common Stock
Dec 18 2024
SELL
Open market or private sale
$711,040 $88.88 p/Share
8,000 Reduced 6.81%
109,491 Common Stock
Dec 18 2024
BUY
Exercise of conversion of derivative security
$42,800 $5.35 p/Share
8,000 Added 6.37%
117,491 Common Stock
Nov 18 2024
SELL
Open market or private sale
$691,040 $86.38 p/Share
8,000 Reduced 6.81%
109,491 Common Stock
Nov 18 2024
BUY
Exercise of conversion of derivative security
$42,800 $5.35 p/Share
8,000 Added 6.37%
117,491 Common Stock
Oct 25 2024
BUY
Exercise of conversion of derivative security
$399,930 $20.93 p/Share
19,108 Added 14.86%
109,491 Common Stock
Oct 18 2024
SELL
Open market or private sale
$4,860,660 $115.73 p/Share
42,000 Reduced 31.73%
90,383 Common Stock
Oct 18 2024
BUY
Exercise of conversion of derivative security
$224,699 $5.35 p/Share
42,000 Added 24.08%
132,383 Common Stock
Sep 18 2024
SELL
Open market or private sale
$931,760 $116.47 p/Share
8,000 Reduced 8.13%
90,383 Common Stock
Sep 18 2024
BUY
Exercise of conversion of derivative security
$42,800 $5.35 p/Share
8,000 Added 7.52%
98,383 Common Stock
Sep 03 2024
SELL
Payment of exercise price or tax liability
$698,020 $110.15 p/Share
6,337 Reduced 6.55%
90,383 Common Stock
Aug 19 2024
SELL
Open market or private sale
$629,600 $78.7 p/Share
8,000 Reduced 7.64%
96,720 Common Stock
Aug 19 2024
BUY
Exercise of conversion of derivative security
$42,800 $5.35 p/Share
8,000 Added 7.1%
104,720 Common Stock
Jul 18 2024
SELL
Open market or private sale
$653,280 $81.66 p/Share
8,000 Reduced 7.64%
96,720 Common Stock
Jul 18 2024
BUY
Exercise of conversion of derivative security
$42,800 $5.35 p/Share
8,000 Added 7.1%
104,720 Common Stock
Jun 18 2024
SELL
Open market or private sale
$577,760 $72.22 p/Share
8,000 Reduced 7.64%
96,720 Common Stock
Jun 18 2024
BUY
Exercise of conversion of derivative security
$42,800 $5.35 p/Share
8,000 Added 7.1%
104,720 Common Stock
May 20 2024
SELL
Open market or private sale
$599,440 $74.93 p/Share
8,000 Reduced 7.72%
95,679 Common Stock
May 20 2024
BUY
Exercise of conversion of derivative security
$42,800 $5.35 p/Share
8,000 Added 7.16%
103,679 Common Stock

Also insider at

MTCR
Metacrine, Inc. Healthcare
CRBU
Caribou Biosciences, Inc. Healthcare
AG

Andrew Guggenhime

PRESIDENT AND CFO
San Carlos, CA

Track Institutional and Insider Activities on PCVX

Follow Vaxcyte, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PCVX shares.

Notify only if

Insider Trading

Get notified when an Vaxcyte, Inc. insider buys or sells PCVX shares.

Notify only if

News

Receive news related to Vaxcyte, Inc.

Track Activities on PCVX